Regulatory compliance
The TGA monitors and enforces regulatory compliance in relation to therapeutic goods. This supports consumer protection and a fair market for industry.
Latest articles
- A warning that advertising Ozempic (semaglutide) is prohibitedA warning to social media influencers and advertisers not to advertise this prescription medicine.
- Queensland individual fined $5,328 for alleged unlawful advertising of a complementary medicineThe TGA has issued two infringement notices totalling $5,328 to a Queensland-based individual for the alleged unlawful use of a prohibited representation and endorsement in advertising a listed complementary medicine.
- MDNE Enterprises and an executive officer fined and directed to cease alleged unlawful advertising of nicotine vaping productsDirection and infringement notices given to MDNE Enterprises Pty Ltd for alleged unlawful advertising of nicotine vaping products
Latest publications
- Changes to applying for the evaluation of a new substanceMandatory requirements for applications to vary the Permissible Ingredients Determination under section 26BD of the Therapeutic Goods Act 1989, and accompanying guidelines are intended to come into effect in January 2023.
- Therapeutic goods advertising compliance: 2021-22 Annual ReportOverview of therapeutic goods advertising complaints handling and compliance for 2021-22
- International Coalition of Medicines Regulatory Authorities (ICMRA)Updates to the ICMRA landing page detailing ICMRA's projects and their role during the COVID-19 pandemic.